title: Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator.
abstract: The low density lipoprotein receptor-related protein (LRP), a large scavenger receptor reported to mediate the uptake and degradation of various ligands, emerges as a promising receptor for targeting the invasive behaviour of human cancer cells. However, the accurate function of LRP during tumor invasion seems to be highly dependent on cellular context and remains controversial. The expression patterns of both this receptor and the main proteolytic systems involved in cell invasion were examined in two follicular thyroid carcinoma cell lines exhibiting different invasive phenotypes. We established that a low expression of LRP at the cell surface was associated to elevated extracellular MMP2 and urokinase plasminogen activator (uPA) activities as well as to high invasiveness properties. Surprisingly, neither exogenously added receptor-associated protein, an antagonist of LRP, nor LRP blocking antibodies significantly modified the amount of extracellular MMP2. Furthermore, the invasive phenotype of thyroid carcinoma cells was not related to their matrix metalloproteinases amount since different specific inhibitors of these proteases failed to affect the invasive properties of both cell lines. Additionally, blocking LRP-mediated clearance led to a further increase of the uPA amount and activities and to increased invasiveness in both cell lines. Finally thyroid carcinoma cells aggressiveness was widely increased by exogenous uPA; and anti-uPA antibodies treatments abolished both basal and receptor-associated protein-induced thyroid cell invasion. Overall our results identified the LRP-mediated clearance of uPA as one of the mechanisms involved during the control of human thyroid carcinoma cell invasion.
authors.affiliation: Laboratoire de Biochimie, UMR CNRS 6198, Faculté des Sciences, 51687 Reims, France.
authors.forename: Brice
authors.initials: B
authors.lastname: Sid
authors.forename: Stephane
authors.initials: S
authors.lastname: Dedieu
authors.forename: Nathalie
authors.initials: N
authors.lastname: Delorme
authors.forename: Herve
authors.initials: H
authors.lastname: Sartelet
authors.forename: Geraldine M
authors.initials: GM
authors.lastname: Rath
authors.forename: Georges
authors.initials: G
authors.lastname: Bellon
authors.forename: Laurent
authors.initials: L
authors.lastname: Martiny
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D002277:Carcinoma / Q000201:enzymology / Q000473:pathology*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000737:chemistry; D006801:Humans; D026503:Low Density Lipoprotein Receptor-Related Protein-1 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020778:Matrix Metalloproteinase 2 / Q000032:analysis / Q000378:metabolism; D009361:Neoplasm Invasiveness; D013964:Thyroid Neoplasms / Q000201:enzymology / Q000473:pathology*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
chemical_list: D000906:Antibodies; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D014568:Urokinase-Type Plasminogen Activator; D020778:Matrix Metalloproteinase 2